Exact Sciences (EXAS) Earnings: 2025 Revenue Forecast and Q4 Results Unveiled

Exact Sciences on Smartkarma

Analyst coverage on Smartkarma by Baptista Research delves into Exact Sciences Corporation’s recent performance in the third quarter of 2024. The report highlights a mix of achievements and challenges faced by the company, showcasing a positive financial trajectory. Exact Sciences saw a 13% year-over-year surge in total revenue to $709 million, propelled by the increasing adoption of Cologuard and the international expansion of Oncotype DX. Furthermore, a noteworthy 75% uptick in adjusted EBITDA to $99 million and a record free cash flow of $113 million underscore the company’s significant strides in enhancing operational efficiency.

A look at Exact Sciences Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Exact Sciences Corp., focused on developing a non-invasive molecular screening test for early detection and prevention of colorectal cancer, shows a promising long-term outlook based on its Smartkarma Smart Scores. With a high Growth score of 4, the company is positioned well for future expansion and development in the field of cancer screening. Additionally, a Resilience score of 3 indicates the company’s ability to withstand market challenges and maintain its performance.

However, Exact Sciences has lower scores in other areas such as Dividend and Momentum, which may pose challenges in terms of investor attractiveness and short-term performance. Despite this, the company’s overall outlook remains positive, with a Value score of 3 suggesting a fair valuation in the market. Investors may find potential in Exact Sciences for long-term growth and innovation in the fight against colorectal cancer.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma